GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imugene Ltd (ASX:IMU) » Definitions » Ending Cash Position

Imugene (ASX:IMU) Ending Cash Position : A$139.39 Mil (As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Imugene Ending Cash Position?

Imugene's Ending Cash Position for the quarter that ended in Dec. 2023 was A$139.39 Mil.

Imugene's quarterly Ending Cash Position declined from Dec. 2022 (A$161.91 Mil) to Jun. 2023 (A$153.15 Mil) and declined from Jun. 2023 (A$153.15 Mil) to Dec. 2023 (A$139.39 Mil).

Imugene's annual Ending Cash Position increased from Jun. 2021 (A$29.49 Mil) to Jun. 2022 (A$99.89 Mil) and increased from Jun. 2022 (A$99.89 Mil) to Jun. 2023 (A$153.15 Mil).

Imugene Ending Cash Position Historical Data

The historical data trend for Imugene's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imugene Ending Cash Position Chart

Imugene Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.05 30.11 29.49 99.89 153.15

Imugene Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 118.41 99.89 161.91 153.15 139.39

Imugene Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Imugene's Ending Cash Position for the fiscal year that ended in Jun. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=99.888+53.263
=153.15

Imugene's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=153.151+-13.759
=139.39

Imugene Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Imugene's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Imugene (ASX:IMU) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imugene Ltd (ASX:IMU) » Definitions » Ending Cash Position
Comparable Companies
ASX:IMM ASX:BOT ASX:PYC ASX:OPT ASX:CUV ASX:RAC ASX:DXB ASX:PIQ ASX:ALA ASX:RCE OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
IUGNF:USA
Address
4-6 Bligh Street, Suite 12.01, Level 12, Sydney, NSW, AUS, 2000
Website
https://www.imugene.com
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its product includes HER-Vaxx,PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment being the Research and Development of oncolytic immunotherapies.

Imugene (ASX:IMU) Headlines

No Headlines